Gene therapies for high-grade gliomas: from the bench to the bedside.
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
30 06 2020
30 06 2020
Historique:
received:
30
05
2020
accepted:
01
06
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
29
6
2021
Statut:
epublish
Résumé
Gene therapy is the most attractive therapeutic approach against high-grade gliomas (HGGs). This is because of its theoretical capability to rework gene makeup in order to yield oncolytic effects. However, some factors still limit the upgrade of these therapies at a clinical level of evidence. We report an overview of glioblastoma gene therapies, mainly focused on the rationale, classification, advances and translational challenges. An extensive review of the online literature on gene therapy for HGGs was carried out. The PubMed/MEDLINE and ClinicalTrials.gov websites were the main sources. Articles in English published in the last five years were sorted according to the best match with the multiple relevant keywords chosen. A descriptive analysis of the clinical trials was also reported. A total of 85 articles and 45 clinical trials were selected. The main types of gene therapies are the suicide gene, tumor suppressor gene, immunomodulatory gene and oncolytic therapies (virotherapies). The transfer of genetic material entails replication-deficient and replication-competent oncolytic viruses and nanoparticles, such as liposomes and cationic polymers, each of them having advantages and drawbacks. Forty-eight clinical trials were collected, mostly phase I/II. Gene therapies constitute a promising approach against HGGs. The selection of new and more effective target genes, the implementation of gene-delivery vectors capable of greater and safer spreading capacity, and the optimization of the administration routes constitute the main translational challenges of this approach.
Sections du résumé
BACKGROUND
Gene therapy is the most attractive therapeutic approach against high-grade gliomas (HGGs). This is because of its theoretical capability to rework gene makeup in order to yield oncolytic effects. However, some factors still limit the upgrade of these therapies at a clinical level of evidence. We report an overview of glioblastoma gene therapies, mainly focused on the rationale, classification, advances and translational challenges.
METHODS
An extensive review of the online literature on gene therapy for HGGs was carried out. The PubMed/MEDLINE and ClinicalTrials.gov websites were the main sources. Articles in English published in the last five years were sorted according to the best match with the multiple relevant keywords chosen. A descriptive analysis of the clinical trials was also reported.
RESULTS
A total of 85 articles and 45 clinical trials were selected. The main types of gene therapies are the suicide gene, tumor suppressor gene, immunomodulatory gene and oncolytic therapies (virotherapies). The transfer of genetic material entails replication-deficient and replication-competent oncolytic viruses and nanoparticles, such as liposomes and cationic polymers, each of them having advantages and drawbacks. Forty-eight clinical trials were collected, mostly phase I/II.
CONCLUSION
Gene therapies constitute a promising approach against HGGs. The selection of new and more effective target genes, the implementation of gene-delivery vectors capable of greater and safer spreading capacity, and the optimization of the administration routes constitute the main translational challenges of this approach.
Identifiants
pubmed: 32608374
doi: 10.23750/abm.v91i7-S.9953
pmc: PMC7975827
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
32-50Références
Proc Biol Sci. 2015 Dec 22;282(1821):20143003
pubmed: 26702034
Neuro Oncol. 2014 Oct;16 Suppl 4:iv1-63
pubmed: 25304271
Int J Exp Pathol. 2004 Oct;85(4):177-90
pubmed: 15312123
Cancer Lett. 2004 Oct 28;214(2):205-13
pubmed: 15363547
Mol Ther. 2004 Nov;10(5):958-66
pubmed: 15509513
Annu Rev Pathol. 2014;9:1-25
pubmed: 23937436
Cancer Res. 2009 Dec 1;69(23):8932-40
pubmed: 19920199
Transl Res. 2013 Apr;161(4):339-54
pubmed: 23246627
World Neurosurg. 2019 Jan 22;:
pubmed: 30677572
J Neurooncol. 2003 Dec;65(3):269-78
pubmed: 14682377
Neuro Oncol. 2014 Mar;16(3):334-51
pubmed: 24470549
Cancer Res. 2004 Sep 15;64(18):6610-5
pubmed: 15374975
Glia. 1995 Nov;15(3):308-27
pubmed: 8586466
Gene Ther. 1996 Jun;3(6):491-5
pubmed: 8789798
Nat Med. 1999 Aug;5(8):881-7
pubmed: 10426310
Turk Neurosurg. 2019;29(6):875-886
pubmed: 31452176
Nat Med. 2002 May;8(5):527-31
pubmed: 11984600
Oncogene. 2000 Jan 6;19(1):2-12
pubmed: 10644974
Tumour Biol. 2013 Aug;34(4):2063-74
pubmed: 23737287
Nat Biotechnol. 2014 Apr;32(4):347-55
pubmed: 24584096
Hum Gene Ther. 2010 Apr;21(4):417-26
pubmed: 19899955
Expert Opin Drug Deliv. 2007 Nov;4(6):621-33
pubmed: 17970665
J Natl Cancer Inst. 2003 May 7;95(9):652-60
pubmed: 12734316
Surg Neurol Int. 2017 Jun 13;8:117
pubmed: 28680736
Mol Ther Nucleic Acids. 2013 Dec 03;2:e136
pubmed: 24301867
New Biol. 1991 Jun;3(6):608-14
pubmed: 1655012
eNeurologicalSci. 2018 Nov 27;14:31-33
pubmed: 30555950
Nat Rev Neurol. 2013 May;9(5):277-91
pubmed: 23609618
Clin Med Oncol. 2009 Apr 8;3:39-52
pubmed: 19777070
Heliyon. 2019 Nov 26;5(11):e02818
pubmed: 31844735
Neuropharmacology. 2017 Jul 1;120:63-80
pubmed: 26905292
Lancet. 2012 May 26;379(9830):1984-96
pubmed: 22510398
Hum Gene Ther. 2000 Jan 1;11(1):77-89
pubmed: 10646641
Biomaterials. 2012 Jan;33(3):916-24
pubmed: 22048008
Hum Gene Ther. 2005 Mar;16(3):339-47
pubmed: 15812229
Mol Oncol. 2017 Feb;11(2):180-193
pubmed: 28098415
Nanomaterials (Basel). 2019 Jan 16;9(1):
pubmed: 30654536
Anticancer Agents Med Chem. 2011 Oct;11(8):739-47
pubmed: 21707496
Clin Cancer Res. 1999 Mar;5(3):637-42
pubmed: 10100717
Cancer Gene Ther. 2009 Feb;16(2):149-60
pubmed: 18670452
J Immunol. 2000 Dec 1;165(11):6620-6
pubmed: 11086107
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Neuro Oncol. 2017 Jul 1;19(7):930-939
pubmed: 28387849
PLoS One. 2015 Oct 06;10(10):e0139603
pubmed: 26441059
Mol Med Rep. 2008 May-Jun;1(3):335-42
pubmed: 21479414
Curr Gene Ther. 2009 Oct;9(5):422-7
pubmed: 19860656
J Virol. 2012 Mar;86(5):2750-9
pubmed: 22171271
Nanotechnology. 2011 Oct 28;22(43):435101
pubmed: 21955528
Mol Ther. 2004 Nov;10(5):967-72
pubmed: 15509514
Cancer Lett. 2016 Jun 1;375(2):263-273
pubmed: 26966000
Int J Nanomedicine. 2012;7:4391-408
pubmed: 22927757
Hum Gene Ther. 1996 Apr 10;7(6):713-20
pubmed: 8919593
Int J Mol Sci. 2018 Sep 17;19(9):
pubmed: 30227679
Curr Oncol Rep. 2000 Sep;2(5):463-72
pubmed: 11122879
Oper Neurosurg (Hagerstown). 2018 Dec 1;15(6):E92-E93
pubmed: 29618124
Expert Rev Neurother. 2015;15(7):741-52
pubmed: 26027432
Science. 2011 Jul 15;333(6040):307
pubmed: 21700836
Biomedicines. 2014 Apr 08;2(2):149-162
pubmed: 28548065
Biomacromolecules. 2001 Fall;2(3):1023-8
pubmed: 11710005
Nanotoxicology. 2014 Aug;8(5):521-32
pubmed: 23642008
Mol Cell Ther. 2014 Jul 08;2:21
pubmed: 26056588
Cancer Gene Ther. 2013 Oct;20(10):544-51
pubmed: 23969884
Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3525-9
pubmed: 8622970
Chem Asian J. 2012 Jan 2;7(1):91-6
pubmed: 22072592
Neuro Oncol. 2004 Jul;6(3):208-17
pubmed: 15279713
Oncogene. 1997 Oct 23;15(17):2049-57
pubmed: 9366522
Mol Ther. 2014 Apr;22(4):774-85
pubmed: 24441399
Hum Gene Ther. 1996 Aug 1;7(12):1465-82
pubmed: 8844206
J Pharm Pharmacol. 2013 May;65(5):634-51
pubmed: 23600380
Hum Gene Ther. 2004 Jan;15(1):77-86
pubmed: 14965379
Neurotherapeutics. 2014 Oct;11(4):817-39
pubmed: 25159276
Nat Med. 2015 Feb;21(2):121-31
pubmed: 25654603
Nanotechnol Sci Appl. 2010 Sep 20;3:53-63
pubmed: 24198471
Cancer Res. 2005 Apr 1;65(7):2832-9
pubmed: 15805284
Cancers (Basel). 2013 Oct 23;5(4):1271-305
pubmed: 24202446
EMBO Mol Med. 2013 Nov;5(11):1642-61
pubmed: 24106209
Genes Dev. 2012 Apr 15;26(8):756-84
pubmed: 22508724
J Neurooncol. 2003 Dec;65(3):279-89
pubmed: 14682378
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):113-128
pubmed: 26004498
Expert Rev Neurother. 2009 Apr;9(4):505-17
pubmed: 19344302
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
Mol Ther. 2009 Jan;17(1):199-207
pubmed: 18957964
Mol Ther. 2012 Sep;20(9):1689-98
pubmed: 22547150
Cancer Res. 2003 May 1;63(9):2300-5
pubmed: 12727853
J Neurol Neurosurg Psychiatry. 2013 Feb;84(2):213-22
pubmed: 22993449
World Neurosurg. 2019 Nov;131:10-17
pubmed: 31356977
Science. 2014 Nov 28;346(6213):1258096
pubmed: 25430774
Neuro Oncol. 2015 Mar;17 Suppl 2:ii24-ii36
pubmed: 25746089
Discov Med. 2010 Oct;10(53):293-304
pubmed: 21034670
J Control Release. 1999 Aug 5;60(2-3):149-60
pubmed: 10425321
Neuro Oncol. 2012 Feb;14(2):145-59
pubmed: 22070930
Nat Med. 1997 Jun;3(6):639-45
pubmed: 9176490
Cancer Gene Ther. 2000 Mar;7(3):486-94
pubmed: 10766355
Gene Ther. 2003 Jun;10(11):935-40
pubmed: 12756413
Expert Opin Biol Ther. 2016;16(2):143-59
pubmed: 26642082
Int J Pharm. 2013 Mar 10;445(1-2):79-87
pubmed: 23384727
Cell Adh Migr. 2008 Jul-Sep;2(3):186-91
pubmed: 19262115
Turk Neurosurg. 2018;28(3):454-461
pubmed: 28481388
J Neurooncol. 2003 Dec;65(3):261-7
pubmed: 14682376
Cancer Res. 1996 Feb 15;56(4):694-9
pubmed: 8630997
Cancer Gene Ther. 2005 Oct;12(10):835-48
pubmed: 15891772
World Neurosurg. 2018 Aug;116:e340-e353
pubmed: 29751183
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Am J Pathol. 2012 Oct;181(4):1126-41
pubmed: 22858156
Neurosurgery. 1999 Nov;45(5):1093-104
pubmed: 10549925
Cancer Res. 2002 Aug 15;62(16):4656-62
pubmed: 12183422
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6803-8
pubmed: 10841575
Hum Gene Ther. 2000 Nov 1;11(16):2197-205
pubmed: 11084677